Progenics Pharmaceuticals to Participate in Investor Conferences

TARRYTOWN, N.Y., Mar 29, 2012 (GlobeNewswire via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will present at two upcoming investor conferences in New York City: -- 11th Annual Needham Healthcare Conference 10:40 a.m. ET, Tuesday, April 3 -- 19th Annual Future Leaders in the Biotech Industry Conference 2:30 p.m. ET, Friday, April 20 Both presentations will be webcast live and will be archived for 30 days on the Events page of Progenics' website.

About Progenics Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company dedicated to developing innovative medicines to treat disease, with a focus on cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR(R), to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR by patients with chronic, non-cancer pain. Salix and Progenics have announced positive highly statistically significant results from a phase 3 trial of oral methylnaltrexone in chronic, non-cancer pain subjects with opioid-induced constipation.

The Progenics Pharmaceuticals Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9678 Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this release.

(PGNX-G) Editor's Note: For more information, please visit www.progenics.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com SOURCE: Progenics Pharmaceuticals Inc.

CONTACT: Amy Martini Corporate Affairs (914) 789-2816 amartini@progenics.com

[ Back To Homepage ]

Real time alerts

The World's Largest Communications And Technology Community

Technology Marketing Corporation,
800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.

» About » Contact » Advertise